Explore the evidence behind red light therapy, how it affects mitochondrial function, and practical protocols for anti-aging benefits.
Red light therapy, also known as photobiomodulation (PBM), has transitioned from fringe wellness trend to evidence-backed intervention. By exposing the body to specific wavelengths of red and near-infrared light, this therapy appears to enhance mitochondrial function, reduce inflammation, and support cellular repair mechanisms central to aging.
Red light therapy operates through a remarkably elegant mechanism. When red (630-660nm) or near-infrared (810-850nm) light penetrates the skin, it is absorbed by cytochrome c oxidase, a key enzyme in the mitochondrial electron transport chain.
The result is enhanced cellular function across multiple tissue types—from skin to brain to muscle.
In 2026, *Nature* published a comprehensive review titled "The surprising science behind red-light therapy — and how it really works," marking a significant milestone in the field's legitimacy. The review confirmed that mitochondria — specifically the enzyme cytochrome c oxidase — are the primary cellular target, with red and near-infrared wavelengths boosting ATP production and improving blood flow via nitric oxide release.
The review also summarised a 2025 multi-specialist consensus that concluded photobiomodulation is safe and effective for peripheral neuropathy, androgenic alopecia, acute radiation dermatitis, and certain types of ulcers. The FDA approved a red-light device for oral mucositis (a painful complication of chemotherapy) in the same period. Crucially, the Nature review noted that humans today receive far less red and near-infrared light than they would have historically — a consequence of spending more time indoors under LED and fluorescent lighting, which are deficient in these wavelengths.